Immunotherapy with checkpoint inhibitors for lung cancer: Novel agents, biomarkers and paradigms

Future Oncology

Volumn 12, Issue 4, 2016, Pages 551-564

  Monteiro, Inês De Paula ^a   Califano, Raffaele ^b,c   Mountzios, Giannis ^d   De Mello, Ramon Andrade ^a,e,f  

^a University of Porto   (Portugal)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e UNIVERSITY OF ALGARVE   (Portugal)

^f Instituto do Cancer do Ceara   (Brazil)

Author keywords

biomarkers; immune related response criteria; immunotherapy; lung cancer; nivolumab

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PD1; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGIC FACTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; DRUG EFFICACY; HUMAN; IMMUNE SYSTEM; INTENTION TO TREAT ANALYSIS; LUNG CANCER; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84957644044     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.309     Document Type: Review

References (50)

1. American Cancer Society. Global Cancer Facts & Figures 3rd Edition (2015). www.cancer.org
2. Network NCCN: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer 2015 (Version 5.2015). www.nccn.org
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
4. Matsushita H, Vesely MD, Koboldt DC et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385), 400-404 (2012).
5. Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy. Lancet Respir. Med. 1(7), 551-563 (2013).
6. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv. Cancer Res. 128, 95-139 (2015).
7. Miller JF, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 27(4), 439-449 (2015).
8. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111-122 (2007).
9. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16-25 (2014).
10. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
11. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33(18), 2004-2012 (2015).
12. Gettinger S, Rizvi N, Chow L et al. 1054PD Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) or erlotinib (ERL) in advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 25(Suppl. 4), iv361-iv372 (2014).
13. Gettinger SN, Hellmann MD, Shepherd FA et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. Presented at: ASCO Annual Meeting ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015.
14. Rizvi NA, Chow LQM, Borghaei H et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. Presented at: ASCO Annual Meeting 2014. Chicago, IL, USA, 30 May-3 June 2014.
15. Antonia S, Gettinger S, Chow LM et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim Phase I results. J. Clin. Oncol. 32(Suppl. 15), Abstract 8023 (2014).
16. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a Phase 2, single-arm trial. Lancet Oncol. 16(3), 257-265 (2015).
17. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 123-135 (2015).
18. Paz-Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting ASCO Annual Meeting 2015. Chicago, IL, USA. 29 May-2 June 2015.
19. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018-2028 (2015).
20. Herbst RS, Soria J-C, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-567 (2014).
21. Spira AI, Park K, Mazieres J et al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). Presented at: ASCO Annual Meeting ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015.
22. Segal NH, Antonia SJ, Brahmer JR et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J. Clin. Oncol. 32(Suppl. 5), Abstract 3002 (2014).
23. Rizvi NA, Brahmer JR, Ou S-HI et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015.
24. Villaruz LC, Kalyan A, Zarour H, Socinski MA. Immunotherapy in lung cancer. Transl. Lung Cancer Res. 3(1), 2-14 (2014).
25. Jure-Kunkel M, Masters G, Girit E et al. Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol. Immunother. 62(9), 1533-1545 (2013).
26. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
27. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30(17), 2046-2054 (2012).
28. Forde PM, Kelly RJ, Brahmer JR. New strategies in lung cancer: translating immunotherapy into clinical practice. Clin. Cancer. Res. 20(5), 1067-1073 (2014).
29. Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II trial. Ann. Oncol. 24(1), 75-83 (2013).
30. Zatloukal P, Heo D, Park K et al. Randomized Phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(15S), Abstract 8071 (2009).
31. Domingues D, Turner A, Silva MD et al. Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy 6(11), 1221-1235 (2014).
32. Antonia SJ, Bendell JC, Taylor MH et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Presented at: ASCO Annual Meeting ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May-2 June 2015.
33. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107(9), 4275-4280 (2010).
34. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73(12), 3591-3603 (2013).
35. Mu C-Y, Huang J-A, Chen Y, Chen C, Zhang X-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28(3), 682-688 (2011).
36. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14(4), 847-856 (2015).
37. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer. Res. 20(19), 5064-5074 (2014).
38. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J. Intern. Med. 4(2), 627-635 (2013).
39. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006-2017 (2015).
40. Rizvi NA, Hellmann MD, Snyder A et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124-128 (2015).
41. Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29(6), 610-618 (2011).
42. Galon J, Pagès F, Marincola FM et al. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10(1), (2012).
43. Remark R, Becker C, Gomez JE et al. The non-small cell lung cancer immune contexture: a major determinant of tumor characteristics and patient outcome. Am. J. Respir. Crit. Care Med. 191(4), 377-390 (2014).
44. Donnem T, Hald SM, Paulsen E-E et al. Stromal CD8+ T cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin. Cancer. Res. 21(11), 2635-2643 (2015).
45. Eisenhauer E, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
46. Wolchok JD, Hoos A, O'day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer. Res. 15(23), 7412-7420 (2009).
47. De Castro J, Cobo M, Isla D et al. Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. Clin. Transl. Oncol. 17(1), 11-23 (2015).
48. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19(14), 3936-3943 (2013).
49. De Mello RA, Pousa I, Pereira D. Nivolumab for advanced squamous cell lung cancer: what are the next steps? Lancet Oncol. 16(3), 234-235 (2015).
50. Romano E, Romero P. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. J. Immunother. Cancer doi:10.1186/s40425-015-0059-z (2015) (Epub ahead of print).